MTOR and thyroid cancer: Because of the signaling convergence of both somatostatin receptor and mTOR pathway and the implication of both pathways in thyroid cancer, a therapeutic strategy of combined somatostatin analogue therapy and mTOR inhibition is likely to achieve improved efficacy.